Literature DB >> 1220760

Extracorporeal immunoadsorption of circulating specific serum factors in cancer patients.

E Langvad, H Hydén, H Wolf, N Kroeigaard.   

Abstract

Circulating serum factors have been said to abrogate the effects of immune response in cancer, i.e. "blocking" and "antigenic inhibition". The aim of this investigation was to isolate such specific factors in a purified and native state. F(ab)2 fragments isolated from hypernephroma were insolubilized on the surfaces of an extracorporeal perfusion chamber which was inserted into the circulation by means of an arterio-venous shunt. As a result, 3 proteins not present in normal serum were isolated and eluted for further study. In immunoelectrophoresis the 3 proteins were specifically precipitated by heterolgous (rabbit) antihypernephroma serum but not by anti-serum directed against normal serum components. Moreover C9 components, C3 activator and C3 were isolated in the chamber, the latter complement factor in large concentrations. This further sustained that specific antigen-antibody reactions had occurred in the chamber. One of the 2 patients studied were perfused for 60 h and 40 min. During this period 450 litres of blood were brought into intimate contact with the immunoadsorbent. Proteins in amounts sufficient for immunochemical analysis were isolated within 3 h.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1220760      PMCID: PMC2025021          DOI: 10.1038/bjc.1975.279

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  Autoantibodies with antilipoprotein specificity and hypolipoproteinemia in patients with cancer.

Authors:  W Riesen; G Noseda; A Morell; R Bütler; S Barandun; U E Nydegger
Journal:  Cancer Res       Date:  1975-03       Impact factor: 12.701

2.  A new specific chemotherapy: a pilot study with an extracorporeal chamber.

Authors:  H Hydén; L E Gelin; S Larsson; A Saarne
Journal:  Rev Surg       Date:  1974 Sep-Oct

3.  Circulating immune complexes in human neuroblastoma: direct assay and role in blocking specific cellular immunity.

Authors:  D G Jose; R Seshadri
Journal:  Int J Cancer       Date:  1974-06-15       Impact factor: 7.396

Review 4.  The subunit structure of transplantation antigens.

Authors:  L Rask; L Ostberg; B Lindblom; Y Fernstedt; P A Peterson
Journal:  Transplant Rev       Date:  1974

5.  Cellular and humoral immunity to different types of human neoplasms.

Authors:  I Hellström; K E Hellström; G E Pierce; J P Yang
Journal:  Nature       Date:  1968-12-28       Impact factor: 49.962

6.  The cross-linking of proteins with glutaraldehyde and its use for the preparation of immunoadsorbents.

Authors:  S Avrameas; T Ternynck
Journal:  Immunochemistry       Date:  1969-01

7.  Suggestive evidence for in vivo binding of specific antitumor antibodies of human melanomas.

Authors:  R K Gupta; D L Morton
Journal:  Cancer Res       Date:  1975-01       Impact factor: 12.701

8.  IgA as a blocking factor in human malignant melanoma.

Authors:  P A O'Neill; M M Romsdahl
Journal:  Immunol Commun       Date:  1974

9.  Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells.

Authors:  K Irie; R F Irie; D L Morton
Journal:  Science       Date:  1974-11-01       Impact factor: 47.728

10.  Serum mediated inhibition of the immunological reactions of the patient to his own tumour: a possible role for circulating antigen.

Authors:  G A Currie; C Basham
Journal:  Br J Cancer       Date:  1972-12       Impact factor: 7.640

View more
  2 in total

1.  Nature of antigens and antibodies in immune complexes isolated by staphylococcal protein A from plasma of melanoma patients.

Authors:  R K Gupta; A M Leitch; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

2.  Detection of tumour associated antigen in eluates from protein A columns used for ex vivo immunoadsorption of plasma from melanoma patients by radioimmunoassay.

Authors:  R K Gupta; A M Leitch; D L Morton
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.